SB-728-T: Phase I/II started

Sangamo began the open-label, dose-escalation Phase I/II SB-728-1101 trial evaluating 200, 500 and 1,000 mg cyclophosphamide a day prior to SB-727-T infusion in at least 9 HIV-infected patients on HAA...